13:12:47 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-15 Kvartalsrapport 2024-Q1
2024-03-28 Ordinarie utdelning CESSA 0.00 DKK
2024-03-27 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-12 Kvartalsrapport 2023-Q1
2023-03-24 Ordinarie utdelning CESSA 0.00 DKK
2023-03-23 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-18 Kvartalsrapport 2022-Q3
2022-11-04 Extra Bolagsstämma 2022
2022-08-19 Kvartalsrapport 2022-Q2
2022-04-19 Kvartalsrapport 2022-Q1
2022-03-18 Ordinarie utdelning CESSA 0.00 DKK
2022-03-17 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-04-19 Kvartalsrapport 2021-Q1
2021-03-29 Ordinarie utdelning CESSA 0.00 DKK
2021-03-26 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2022-11-14 14:06:21

København, Denmark, November 14, 2022 - The results of the rights issue announced on October 19, 2022 for which the subscription period ended on November 9,  2022 (the "Rights Issue" or the "Offering") in Cessatech A/S ("Cessatech" or the "Company"), show that 721,991 Units, corresponding to approximately 47.3 percent of the Offering were subscribed for with subscription rights. In addition, notifications have been received to subscribe for 218,041 Units without the support of subscription rights, corresponding to approximately 14.3 percent of the Offering. The underwriters are therefore allocated approximately 18.5 percent of the Rights Issue, resulting in the Offering being 80 percent subscribed. The Company will receive total proceeds of approximately DKK 14.7 million before costs related to the Offering, and upon full exercise of warrants, Cessatech will receive additional proceeds of up to DKK 22 million before costs related to the Offering.

As a result of the Offering, the number of shares in the Company will increase by 7,334,970 shares to  13,447,505 shares, equal to a nominal share capital after the Offering of DKK 2,689,501. If all the warrants issued in connection with the Offering are exercised, the number of shares will increase with an additional  3,667,485 shares to 17,114,990 shares in total and a nominal share capital of DKK 3,422,998.

Those who have subscribed for Units without the support of subscription rights will be allotted Units in accordance with the principles set out in the Offering Memorandum published by the Company on October 20, 2022. Upon allocation, the settlement note is expected to be issued around November 16, 2022. Subscribed and allotted Units shall be paid in cash in DKK in accordance with the instructions on the settlement note. Nominee-registered shareholders will be notified of allotment in accordance with the nominee's routines.

In connection with the Offering, a number of investors have made underwriting commitments. For underwriting commitments a compensation of 12 percent of the underwritten amount is paid in cash or alternatively 15 percent of the underwritten amount in the form of newly issued Units in the Company. Underwriters who wish to receive underwriting compensation in the form of Units must notify the Company no later than November 16, 2022. Units issued as underwriting compensation carry the same terms as Units in the Offering.

Advisors
Translution Capital acts as financial advisors to the Company in connection with the Offering. Nordic Issuing is the Company's issuing agent whereas Elmann Law Firm is the Company's legal advisor in connection with the Offering.

This disclosure contains information that Cessatech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14-11-2022 14:06 CET.